Advertisement
For women

Hours Worked Impacted by Kids for Female, Not Male Doctors

0
Findings from a national sample of dual-physician couples
Adoption of specialty access standards has not improved access to specialists

Specialist Access No Better With Adoption of Access Standards

0
No notable improvement in timely access to specialty services following implementation of standards
Many studies used to support U.S. Food and Drug Administration approval of high-risk medical device modifications are not controlled; and efficacy of drugs granted accelerated approval is often confirmed three years after approval

Studies Used for FDA Approval of Device Changes Often Low Quality

0
And, efficacy of drugs granted accelerated approval often confirmed only years after approval
Probiotic administration during the first six months of life does not reduce the incidence of eczema at 2 years of age or asthma at 5 years of age

Probiotics in Infancy Do Not Reduce Incidence of Eczema

0
Probiotics in first six months of life do not reduce incidence of eczema at age 2, asthma at age 5
Strategies can help to prevent medical practice billing errors

Guidance Provided for Preventing Practice Billing Errors

0
Practices should have a compliance plan and policy and someone responsible for enforcing it

Epigenetic Markers Correlate With Allergic Rhinitis Severity

0
Potential markers identified may be future therapeutic targets for allergic rhinitis

Revenue Exceeds Expenditures for Many ABMS Member Boards

0
Change in net balance of American Board of Medical Specialties member boards grew from 2003 to 2013

Signature ID’d for Allergen-Specific Type 2 Helper Cells

0
Method for identifying pathogenic T cells implicated in allergic response may allow use as biomarker, target

July 2017 Briefing – Allergy

0
Here are what the editors at HealthDay consider to be the most important developments in Allergy for July 2017. This roundup includes the latest...
Allergen immunotherapy may be cost-effective for allergic rhinitis

Cost-Effectiveness of Allergen Immunotherapy Evaluated

0
AIT may be cost-effective for allergic rhinitis and in high-risk groups for venom allergy